CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 912 enrolled
Drug / intervention
Surveyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03070236
NCT03070236N/AActive

PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

Dana-Farber Cancer Institute·interventional·Posted Mar 3, 2017·Updated Feb 3, 2026

In Brief

A clinical study evaluating Survey for Breast Cancer. Active but no longer recruiting, targeting 912 participants across 6 sites.

Detailed Summary

This research study is evaluating how patients feel physically and emotionally after a prior breast biopsy for specific breast conditions (including atypical lesions such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and/or ductal carcinoma in situ (DCIS))

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

N/AActive
20172018201920202021202220232024202520262027202820292030
First PostedMar 3, 2017
Enrollment StartDec 1, 2017
Primary CompletionMay 27, 2019
Study CompletionFeb 25, 2030
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.3 years ago

Interventions

Surveyother

Select questions will be ask in the survey